Please Confirm

This website is an information resource intended only for Healthcare Professionals from U.S. who are interested in information on Clinical Research and EMD Serono clinical trials.

By clicking "I am a healthcare professional" you are declaring and confirming that you are a Healthcare Professional inside the U.S. and have read and understood this disclaimer.

Leaving TargetingMET website

You are leaving TargetingMET Clinical Trials page. This link will take you to a website where our Terms of Use do not apply. Merck does not control the content of these websites.

OUR TRIALS

Welcome to our clinical trial platform informing about our research of tepotinib. Here, you will find information about tepotinib, an oral drug that blocks the activity of the MET protein in cells, which is currently being studied in clinical trials of cancer that has changes to the MET gene.

Tepotinib is under clinical investigation in various countries. The safety and efficacy of tepotinib must be investigated following the respective national regulations and laws. There is no guarantee that tepotinib will be approved in the sought-after indication by the health authority in your country.

 


Find out more about our tepotinib trials below

INSIGHT 2: Advanced/Metastatic NSCLC With MET amplification and Acquired Resistance to Osimertinib


Please Confirm

This website is an information resource intended only for Healthcare Professionals who are interested in information on Clinical Research and Merck sponsored clinical trials. 

 

By clicking “I am a healthcare professional” you are declaring and confirming that you are a Healthcare Professional and have read and understood this disclaimer.

 

I AM NOT A HEALTHCARE PROFESSIONAL

 

 

tepotinib nsclc insight 2 clinical trial lung icon

LUNG

MET-amplified NSCLC with progression on osimertinib INSIGHT 2 clinical trial lung icon

ADVANCED
METASTATIC

phase 2 tepotinib nsclc insight 2 clinical trial icon

PHASE
2

nsclc insight 2 clinical trial combination therapy tepotinib and osimertinib icon

COMBINATION
THERAPY

 

A phase 2 clinical study of tepotinib combined with osimertinib in patients with advanced or metastatic MET-amplified non-small cell lung cancer (NSCLC) with activating changes in the EGFR gene and resistance to prior osimertinib therapy

ClinicalTrials.gov: NCT03940703

Location: Asia, Europe, North America

Status:

ACTIVE, NOT RECRUITING

US Medical Information: 888-275-7376 - eMediUSA@emdserono.com

Global Communication Center: +49 6151 72 5200 - service@emdgroup.com

Singapore Medical Information: +65 6890 6638 - medinfo_singapore@merckgroup.com


 

VISION: Advanced/Metastatic NSCLC With MET Alterations


Please Confirm

This website is an information resource intended only for Healthcare Professionals who are interested in information on Clinical Research and Merck sponsored clinical trials. 

 

By clicking “I am a healthcare professional” you are declaring and confirming that you are a Healthcare Professional and have read and understood this disclaimer.

 

I AM NOT A HEALTHCARE PROFESSIONAL

 

 

tepotinib nsclc vision clinical trial lung icon

LUNG

tepotinib nsclc vision clinical trial advanced metastatic icon

ADVANCED
METASTATIC

phase 2 tepotinib snsclc vision clinical trial icon

PHASE
2

tepotinib nsclc vision clinical trial monotherapy icon

MONOTHERAPY

A phase 2 clinical study of tepotinib in patients with advanced (locally advanced or metastatic) non-small cell lung cancer (NSCLC) with changes in the MET gene.

ClinicalTrials.gov: NCT02864992

Location: Asia, Europe, North America

Status:

ACTIVE, NOT RECRUITING

US Medical Information: 888-275-7376 - eMediUSA@emdserono.com

Global Communication Center: +49 6151 72 5200 - service@emdgroup.com

Singapore Medical Information: +65 6890 6638 - medinfo_singapore@merckgroup.com

 

  1. National Cancer Institute. NCI Dictionary of Cancer Terms. Accessed January 8, 2024. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/metastatic
  2. National Cancer Institute. Accessed January 8, 2024. https://www.cancer.gov/research/leading-progress/2022-annual-plan-budget-proposal-aag.pdf
  3. National Cancer Institute. SEER Training Modules. Accessed January 8, 2024. https://training.seer.cancer.gov/colorectal/intro/types.html
  4. Cancer.Net. Accessed January 8, 2024. https://www.cancer.net/navigating-cancer-care/how-cancer-treated/personalized-and-targeted-therapies/understanding-targeted-therapy
  5. National Cancer Institute. NCI Dictionary of Cancer Terms. Accessed January 8, 2024. https://www.cancer.gov/search/results?swKeyword=gene+amplification

Learn More About

Clinical Trials